Michael A. Thomas

article 2022

Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens

·doi:10.1016/j.contraception.2022.04.002

ObjectivesTo describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days.Study designThis multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 cycle r…

article 2017

Phthalates may alter macrophage signaling to promote a permissive environment for the initiation of endometriosis

·doi:10.1016/j.fertnstert.2017.07.963

review 2012

Ulipristal acetate as an emergency contraceptive agent

Expert opinion on pharmacotherapy ·doi:10.1517/14656566.2012.705832

INTRODUCTION: Emergency contraceptive agents play a crucial role in preventing unplanned pregnancy. These agents and devices have been studied since the 1960s and have had varied results in terms of side effects and efficacy. A new oral tab…